- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01013155
Bioequivalency Study of Perindopril Erbumine 8 mg Tablet Under Fed Conditions
January 19, 2018 updated by: Roxane Laboratories
A Single Dose, Two-Period, Two-Treatment, Two-Sequence Crossover Bioequivalency Study of Perindopril Erbumine Tablets 8 mg Under Fed Conditions
The objective of this study was to prove the bioequivalence of Perindopril Erbumine 8 mg tablet under fed conditions
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
48
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Texas
-
Houston, Texas, United States, 77042
- Novum Pharmaceutical Research Services
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 45 years (ADULT)
Accepts Healthy Volunteers
Yes
Genders Eligible for Study
All
Description
Inclusion Criteria:
- No clinically significant abnormal findings on the physical examination, medical history, or clinical laboratory results during screening
Exclusion Criteria:
- Positive test for HIV, Hepatitis B, or Hepatitis C.
- Treatment with known enzyme altering drugs.
- History of allergic or adverse response to Perindopril or any comparable or similar product.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: RANDOMIZED
- Interventional Model: CROSSOVER
- Masking: NONE
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
bioequivalence determined by statistical comparison Cmax
Time Frame: 20 Days
|
20 Days
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
May 1, 2007
Primary Completion (ACTUAL)
May 1, 2007
Study Completion (ACTUAL)
May 1, 2007
Study Registration Dates
First Submitted
November 11, 2009
First Submitted That Met QC Criteria
November 12, 2009
First Posted (ESTIMATE)
November 13, 2009
Study Record Updates
Last Update Posted (ACTUAL)
January 23, 2018
Last Update Submitted That Met QC Criteria
January 19, 2018
Last Verified
January 1, 2018
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- PERI-T8-PVFD-1
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Essential Hypertension
-
Addpharma Inc.Completed
-
Universidade Federal de Santa MariaCompletedHealthy Volunteers | Hypertension, EssentialBrazil
-
Cytos Biotechnology AGCompletedMild Essential Hypertension | Moderate Essential HypertensionSwitzerland
-
Sulaiman AlRajhi CollegesUnknownHypertension, Essential | β-hydroxybutyrate
-
BayerCompletedHypertension, EssentialGermany
-
National Taiwan University Hospital Hsin-Chu BranchRecruitingHypertension,Essential | Hypertension, MaskedTaiwan
-
Addpharma Inc.Not yet recruitingHypertension,Essential
-
Instituto de Cardiologia do Rio Grande do SulRecruitingHypertension | Hypertension,EssentialBrazil
-
Federal University of Health Science of Porto AlegreIrmandade Santa Casa de Misericórdia de Porto Alegre; Leonhardt Ventures LLCNot yet recruitingHypertension | Hypertension,Essential
Clinical Trials on perindopril erbumine
-
Roxane LaboratoriesCompletedEssential HypertensionUnited States
-
British Columbia Cancer AgencyBayerCompleted
-
Eli Lilly and CompanyCompletedSmall Cell Lung CancerFrance, Belgium, Spain, United States, Korea, Republic of, Japan, United Kingdom, Turkey
-
Melbourne HealthAnHeart Therapeutics Inc.; Walter and Eliza Hall Institute of Medical ResearchActive, not recruiting
-
Eli Lilly and CompanyAurKa Pharma Inc.CompletedNeoplasms | Breast Neoplasms | Head and Neck Neoplasms | Small Cell Lung Carcinoma | Neoplasm Metastasis | Triple Negative Breast Neoplasms | Solid Tumor, AdultCanada
-
Symplmed Pharmaceuticals LLCCompletedEssential HypertensionUnited States
-
Dexa Medica GroupCompleted
-
Sichuan Haisco Pharmaceutical Group Co., LtdCompleted
-
Sichuan Haisco Pharmaceutical Group Co., LtdCompleted
-
Bayside HealthThe Alfred; Baker Heart Research InstituteCompletedMarfan Syndrome